Advertisement

International Ophthalmology

, Volume 29, Issue 3, pp 127–133 | Cite as

Long-term control of cystoid macular oedema in noninfectious uveitis with Mycophenolate Mofetil

  • Piergiorgio Neri
  • Cesare Mariotti
  • Luca Cimino
  • Lucia Mercanti
  • Alfonso Giovannini
Original Paper

Abstract

Purpose To evaluate the long-term safety and efficacy of Mycophenolate Mofetil (MMF) for the control of cystoid macular oedema (CMO) secondary to noninfectious uveitis (NU). Methods The medical records of 19 consecutive patients with inflammatory CMO treated with MMF were retrospectively reviewed. Patient demographics, best corrected visual acuity (BCVA), fluorescein angiography (FA), and optical coherence tomography (OCT) findings were evaluated. Results There were eight females and 11 males with a mean age of 32.9 ± 8.9 years. After a 1-year follow-up, 18/19 patients (31 eyes, 96.9%, P < 0.05) no longer had signs of CMO, as per their FA and OCT findings; the mean central foveal thickness (CFT) was 167.2 ± 12.8 μm. At the last follow-up, only 3/19 patients, all affected by Behçet panuveitis, had recurrences of CMO. Mean BCVA improved from 0.34 ± 0.14 SD at baseline to 0.65 ± 0.2 SD at last follow-up. Conclusions MMF was safe and effective in controlling CMO and in reducing the uveitis relapse rate in patients not responding to traditional immunosuppressants. Further case–controlled studies are mandatory to validate those preliminary results.

Keywords

Cystoid macular oedema Immunosuppression Mycophenolate Mofetil Uveitis 

Abbreviations

AZA

Azathioprine

BPU

Behçet panuveitis

BS

Birdshot

CSA

Cyclosporine A

IIU

Idiopathic intermediate uveitis

IRV

Idiopathic retinal vasculitis

IVT

Intravitreal triamcinolone

STT

Sub-Tenon triamcinolone

MCP

Multifocal choroiditis with panuveitis

MMF

Mycophenolate mofetil

MTX

Methotrexate

ASAU

Ankylosing spondylitis associated uveitis

PIA

Previous immunosuppressive agents

Sarc

Sarcoidosis

References

  1. 1.
    Nussenblatt RB (1986) Macular alterations secondary to intraocular inflammatory disease. Ophthalmology 93(7):984–988PubMedGoogle Scholar
  2. 2.
    Malinowski SM, Pulido JS, Folk JC (1993) Long-term visual out-come and complications associated with pars planitis. Ophthalmology 100:818–825PubMedGoogle Scholar
  3. 3.
    Chang A, Spaide RF, Yannuzzi LA (1999) Post surgical cystoid macular edema. In: Guyer DR, Yannuzzi LA, Chang S et al (eds) Retina, vitreous, macula, vol 1. Saunders, Philadelphia, pp 239–255Google Scholar
  4. 4.
    Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsinopoulos I, Pavesio CE (2004) Macular edema. Surv Ophthalmol 49(5):470–490PubMedGoogle Scholar
  5. 5.
    Catier A, Tadayoni R, Paques M, Erginay A, Haouchine B, Gaudric A, Massin P (2005) Characterization of macular edema from various etiologies by optical coherence tomography. Am J Ophthalmol 140:200–206PubMedGoogle Scholar
  6. 6.
    Lardenoye CW, van Kooij B, Rothova A (2006) Impact of macular edema on visual acuity in uveitis. Ophthalmology 113(8):1446–1449PubMedCrossRefGoogle Scholar
  7. 7.
    Paolo Ferrante P, Ramsey A, Bunce C, Lightman S (2004) Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin Exp Ophthalmol 32:563–568CrossRefGoogle Scholar
  8. 8.
    Vitale AT, Foster CS (2002) Corticosteroids. In: Foster CS, Vitale AT (eds) Diagnosis and treatment of uveitis. W.B. Saunders, Philadelphia, pp 142–158Google Scholar
  9. 9.
    Neri P, Azuara-Blanco A, Forrester JV (2004) Incidence of glaucoma in patients with uveitis. J Glaucoma 13:461–465PubMedCrossRefGoogle Scholar
  10. 10.
    Jabs DA, Rosenbaum JT, Foster CS et al (2000) Guidelines for the use of immunosuppressive drugs in patients with intraocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130:492–513PubMedCrossRefGoogle Scholar
  11. 11.
    Greenwood AJ, Stanford MR, Graham EM (1998) The role of azathioprine in the management of retinal vasculitis. Eye 12:783–788PubMedGoogle Scholar
  12. 12.
    Bom S, Zamiri P, Lightman S (2001) Use of methotrexate in the management of sight-threatening uveitis. Ocul Immunol Inflamm 9:35–40PubMedCrossRefGoogle Scholar
  13. 13.
    Dick A, Azim M, Forrester J (1997) Immunosuppressive therapy for chronic uveitis: optimizing therapy with steroids steroids and cyclosporin A. Br J Ophthalmol 81:1107–1112PubMedCrossRefGoogle Scholar
  14. 14.
    Kilmartin DJ, Forrester JV, Dick AD (1998) Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm 6:101–109PubMedCrossRefGoogle Scholar
  15. 15.
    Kent D, Vinores SA, Campochiaro PA (2000) Macular oedema: the role of soluble mediatore. Br J Ophthalmol 84:542–545PubMedCrossRefGoogle Scholar
  16. 16.
    Vinores SA, Chan C-C, Vinores MA et al (1998) Increased vascular endothelial growth factor (VEGF) and transforming growth factor-beta (TGF-beta) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization. J Neuroimmunol 89:43–50PubMedCrossRefGoogle Scholar
  17. 17.
    Disel U, Pavdas S, Dogan A, Gulfiliz G, Yavuz S (2004) Effect of colchicine on cyclosporine nephrotoxicity, reduction of TGF-beta overexpression, apoptosis, and oxidative damage: an experimental animal study. Transplant Proc 36(5):1372–1376PubMedCrossRefGoogle Scholar
  18. 18.
    Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF (2003) Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity. Am J Transplant 3(12):1550–1559PubMedCrossRefGoogle Scholar
  19. 19.
    Goldblum R (1993) Therapy of reumathoid arthritis with mycophenolate mofetil. Clin Exp Rheumathol 11(suppl 8):S1117–S1119Google Scholar
  20. 20.
    Enk AH, Knop J (1997) Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet 350:494PubMedCrossRefGoogle Scholar
  21. 21.
    Spatz S, Rudnicka A, McDonald CJ (1978) Mycophenolic acid in psoriasis. Br J Dermatol 98:429–435PubMedCrossRefGoogle Scholar
  22. 22.
    Kilmartin DJ, Forrester JV, Dick AD (1998) Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet 352:35–36PubMedCrossRefGoogle Scholar
  23. 23.
    Thorne JE, Jabs DA, Qazi FA, Nguyen QD, Kempen JH, Dunn JP (2005) Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 112(8):1472–1477PubMedCrossRefGoogle Scholar
  24. 24.
    Siepmann K, Huber M, Stübiger N, Deuter C, Zierhut M (2006) Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis. A retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 244:788–794PubMedCrossRefGoogle Scholar
  25. 25.
    Bloch-Michel E, Nussenblatt RB (1987) International uveitis study group recommendation fro the evaluation of intraocular inflammatory diseases. Am J Ophthalmol 103:234–235PubMedGoogle Scholar
  26. 26.
    The standardization of uveitis nomenclature (SUN) working group (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140:509–516Google Scholar
  27. 27.
    Dick AD (2005) Are we still reluctant to immunosuppress? Clin Exp Ophthalmol 33(1):1–2CrossRefGoogle Scholar
  28. 28.
    Deuter CM, Kotter I, Guenaydin I, Stuebiger N, Zierhut M (2006) Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 26(7):786–791PubMedCrossRefGoogle Scholar
  29. 29.
    Sollinger HW, US Renal Transplant Mycophenolate Mofetil Study Group (1995) Mycophenolate Mofetil for the prevention of acute rejection in primery cadaveric renal allograft recipients. Transplantation 60:225–232PubMedCrossRefGoogle Scholar
  30. 30.
    Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group (1996) A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61:1029–1037CrossRefGoogle Scholar
  31. 31.
    European Mycophenolate Mofetil Cooperative Study Group (1995) Placebo-controlled of mycophenolate mofetil combined wirth cyclosporine and corticosteroids for the prevention of acute rejection. Lancet 345:1321–1325Google Scholar
  32. 32.
    Miehsler W, Reinisch W, Moser G, Gangl A, Vogelsang H (2001) Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn’s disease? Am J Gastroenterol 96(3):782–787PubMedCrossRefGoogle Scholar
  33. 33.
    Benez A, Fierlbeck G (2001) Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil. Br J Dermatol 144(3):638–639PubMedCrossRefGoogle Scholar
  34. 34.
    Nowack R, Gobel U, Klooker P, Hergesell O, Andrassy K, van der Wounde FJ (1999) Mycophenolate mofetil for maintenance therapy of Wegener’s granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 10(9):1965–1971PubMedGoogle Scholar
  35. 35.
    Ninova D, Covarrubias M, Rea DJ, Park WD, Grande JP, Stegall MD (2004) Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. Transplantation 78(3):338–344PubMedCrossRefGoogle Scholar
  36. 36.
    Adler YD, Mansumann U, Zouboulis CC (2001) Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet’s disease. Dermatology 203(4):322–324PubMedCrossRefGoogle Scholar
  37. 37.
    Lau CH, Comer M, Lightmen S (2003) Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Exp Ophthalmol 31(6):487–491CrossRefGoogle Scholar
  38. 38.
    Allison M, Eugui EM (2000) Mycophenolate mofetil and its mechanism of action. Immunopharmacology 47:85–118PubMedCrossRefGoogle Scholar
  39. 39.
    Doycheva D, Deuter C, Stuebiger N, Biester S, Zierhut M (2006) Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol. Published online 6 Jul 2006Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Piergiorgio Neri
    • 1
    • 2
  • Cesare Mariotti
    • 1
    • 2
  • Luca Cimino
    • 3
  • Lucia Mercanti
    • 1
    • 2
  • Alfonso Giovannini
    • 1
    • 2
  1. 1.Neuroscience Department, Ophthalmology SectionPolytechnic University of MarcheAnconaItaly
  2. 2.The Eye ClinicAzienda Ospedaliero-Universitaria, “Ospedali Riuniti”AnconaItaly
  3. 3.Ocular Immunology UnitArcispedale S.M. NuovaReggio EmiliaItaly

Personalised recommendations